Your browser is no longer supported. Please, upgrade your browser.
Settings
IMUC ImmunoCellular Therapeutics, Ltd. daily Stock Chart
IMUC [NYSE]
ImmunoCellular Therapeutics, Ltd.
Index- P/E- EPS (ttm)-0.21 Insider Own- Shs Outstand3.39M Perf Week-17.01%
Market Cap8.10M Forward P/E- EPS next Y-5.20 Insider Trans- Shs Float3.39M Perf Month7.66%
Income-20.60M PEG- EPS next Q-1.20 Inst Own9.00% Short Float6.19% Perf Quarter2437.16%
Sales- P/S- EPS this Y6.30% Inst Trans- Short Ratio0.41 Perf Half Y1043.54%
Book/sh0.10 P/B23.90 EPS next Y27.80% ROA-85.50% Target Price5.00 Perf Year857.92%
Cash/sh4.51 P/C0.53 EPS next 5Y- ROE-133.20% 52W Range0.06 - 4.27 Perf YTD16.59%
Dividend- P/FCF- EPS past 5Y19.30% ROI- 52W High-45.77% Beta0.80
Dividend %- Quick Ratio9.80 Sales past 5Y- Gross Margin- 52W Low3621.87% ATR0.36
Employees6 Current Ratio9.80 Sales Q/Q- Oper. Margin- RSI (14)46.31 Volatility9.11% 15.49%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.90% Profit Margin- Rel Volume0.08 Prev Close2.39
ShortableYes LT Debt/Eq0.00 EarningsFeb 09 AMC Payout- Avg Volume516.42K Price2.32
Recom3.00 SMA20-2.43% SMA5011.09% SMA200250.30% Volume12,996 Change-3.14%
Nov-11-16Downgrade Maxim Group Buy → Hold
Aug-23-16Reiterated Maxim Group Buy $3 → $2
Mar-10-15Reiterated Maxim Group Buy $4 → $3
Jun-02-14Reiterated Maxim Group Buy $12 → $4
Dec-12-13Downgrade MLV & Co Buy → Hold $6 → $1.25
Mar-06-13Reiterated MLV & Co Buy $3.50 → $5
Sep-06-12Initiated Maxim Group Buy $18
Jan-12-17 09:30AM  Latest Reports on ImmunoCellular Therapeutics and Neuralstem as Biotech Industry Scrutiny Grows after President Trump's Comments Accesswire
Dec-14-16 05:04PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financ -6.93%
04:05PM  ImmunoCellular Therapeutics Announces Management Changes PR Newswire
Nov-21-16 07:03AM  Splits Calendar: ImmunoCellular Therapeutics splits before market open today (1:40 ratio) +4,938.17%
06:00AM  ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in Newly Diagnosed Glioblastoma at the Society for Neuro-Oncology Annual Meeting 2016 PR Newswire
Nov-18-16 05:17PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year -6.56%
01:04PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Financials
Nov-16-16 11:56AM  Reverse Splits Don't Leave a Lasting Impression at The Wall Street Journal -15.05%
06:00AM  ImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split PR Newswire
Nov-14-16 04:42AM  Edited Transcript of IMUC earnings conference call or presentation 10-Nov-16 10:00pm GMT
Nov-11-16 08:08AM  ImmunoCellular Therapeutics downgraded by Maxim Group -10.79%
Nov-10-16 04:17PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem +7.26%
04:05PM  ImmunoCellular Therapeutics Announces Third Quarter 2016 Financial Results and Provides Research and Development Update PR Newswire
Nov-04-16 01:15PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-02-16 06:00AM  ImmunoCellular Therapeutics to Report Third Quarter 2016 Financial Results on November 10, 2016 PR Newswire
Sep-22-16 04:14PM  Cryoport and Database Integrations Launch Integrated Solution to Manage Patient and Manufacturer Schedules at Every Stage of the Clinical Trial Logistics Process PR Newswire
Sep-16-16 01:44PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-13-16 09:43AM  5 Biotech Stocks That Are Broker Favorites
Sep-01-16 04:49PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing R -15.03%
Aug-31-16 09:15AM  Latest Report on ImmunoCellular Therapeutics Post Earnings +21.33%
Aug-23-16 11:55AM  Edited Transcript of IMUC earnings conference call or presentation 22-Aug-16 9:00pm GMT
Aug-22-16 04:32PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem +5.18%
04:08PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly Report
04:05PM  ImmunoCellular Therapeutics Announces Second Quarter 2016 Financial Results PR Newswire
Aug-17-16 06:00AM  ImmunoCellular Therapeutics to Report Second Quarter 2016 Financial Results on August 22, 2016 PR Newswire
Aug-09-16 08:45AM  ImmunoCellular Therapeutics Announces Pricing of $7.4 Million Public Offering PR Newswire -32.38%
Jul-25-16 06:00AM  ImmunoCellular Therapeutics Reports Progress in Two Lead Cancer Immunotherapy Programs PR Newswire
Jun-21-16 04:16PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-07-16 04:03PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events +10.13%
06:00AM  ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma PR Newswire
May-23-16 06:00AM  ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on June 2, 2016 PR Newswire
May-19-16 06:00AM  BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase 3 Clinical Trial in Glioblastoma PR Newswire
May-13-16 05:12PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly Report -6.83%
May-12-16 04:40PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem -6.29%
04:10PM  ImmunoCellular Therapeutics Announces First Quarter 2016 Financial Results PR Newswire
May-09-16 03:45PM  CYRX: More Shots on Goal from New Accounts, New Capabilities Zacks Small Cap Research
May-06-16 06:00AM  ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma PR Newswire
May-04-16 06:00AM  ImmunoCellular Therapeutics to Report First Quarter 2016 Financial Results on May 12, 2016 PR Newswire
Mar-31-16 12:31PM  Edited Transcript of IMUC earnings conference call or presentation 30-Mar-16 9:00pm GMT
Mar-30-16 04:41PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem +6.37%
04:15PM  ImmunoCellular Therapeutics Announces 2015 Financial Results PR Newswire
Mar-29-16 06:11AM  ImmunoCellular Therapeutics to Report 2015 Financial Results on March 30, 2016 at noodls -6.46%
06:00AM  ImmunoCellular Therapeutics to Report 2015 Financial Results on March 30, 2016 PR Newswire
Mar-07-16 06:00AM  ImmunoCellular Therapeutics to Present at ROTH Conference on March 16, 2016 PR Newswire +10.54%
Mar-03-16 08:00AM  Cryoport Supports ImmunoCellular Therapeutics' 120-Site Phase III Clinical Trial With Cold Chain Logistics PR Newswire
Mar-02-16 04:24PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-16 06:00AM  ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University to Advance Stem-to-T-Cell Program PR Newswire +7.31%
Feb-01-16 06:20AM  ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 8, 2016 at noodls +5.26%
06:00AM  ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 8, 2016 PR Newswire
Jan-27-16 06:23AM  ImmunoCellular Therapeutics Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms at noodls
06:00AM  ImmunoCellular Therapeutics Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms PR Newswire
Jan-04-16 11:34AM  A Look at Four Brain Cancer Companies for 2016 Accesswire
Dec-17-15 09:00AM  ImmunoCellular Therapeutics' Andrew Gengos Interviewed by The Life Sciences Report Marketwired
Dec-14-15 06:00AM  ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumour Consortium for ICT-107 Phase 3 Registrational Trial in Glioblastoma PR Newswire
Dec-07-15 08:30AM  ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing PR Newswire
08:30AM  ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing CNW Group
06:00AM  ImmunoCellular Therapeutics Establishes Agreement with Alliance Foundation Trials, LLC for ICT-107 Phase 3 Registrational Trial in Glioblastoma PR Newswire
Dec-04-15 09:00AM  Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report Marketwired
Dec-01-15 03:07PM  NYSE, Nasdaq and OTC Companies to Present Online to Investors on December 3 PR Newswire
03:07PM  NYSE, Nasdaq and OTC Companies to Present Online to Investors on December 3 CNW Group
08:30AM  ImmunoCellular Therapeutics to Webcast, Live, at VirtualInvestorConferences.com December 3 PR Newswire
08:30AM  ImmunoCellular Therapeutics to Webcast, Live, at VirtualInvestorConferences.com December 3 CNW Group
06:00AM  ImmunoCellular Therapeutics Establishes Agreement with EORTC for ICT-107 Phase 3 Registrational Trial in Glioblastoma PR Newswire
Nov-29-15 04:30AM  Should You Avoid Nuverra Environmental Solutions Inc (NES)? at Insider Monkey
Nov-26-15 09:09AM  Do Hedge Funds Love LiqTech International Inc (LIQT)? at Insider Monkey
Nov-25-15 06:20AM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-24-15 04:30PM  ImmunoCellular Therapeutics Ltd to Discuss ICT-107 Program Call scheduled for 4:30 pm ET today
Nov-23-15 04:05PM  ImmunoCellular Therapeutics to Host Conference Call and Webcast to Discuss ICT-107 Program in Newly Diagnosed Glioblastoma on November 24, 2015 PR Newswire
06:04AM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-20-15 06:00AM  ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015 PR Newswire -17.15%
Nov-19-15 04:18PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Nov-12-15 06:00AM  ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program PR Newswire
Nov-10-15 10:02PM  Edited Transcript of IMUC earnings conference call or presentation 10-Nov-15 10:00pm GMT
05:00PM  ImmunoCellular Therapeutics Ltd Earnings Call scheduled for 5:00 pm ET today
04:33PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem
04:05PM  ImmunoCellular Therapeutics Announces Third Quarter 2015 Financial Results PR Newswire
Nov-09-15 06:17PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly Report
Oct-30-15 04:18PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Oct-27-15 06:00AM  ImmunoCellular Therapeutics to Report Third Quarter 2015 Financial Results on November 10, 2015 PR Newswire
Oct-07-15 04:23PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-24-15 05:02PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Change in Directors or Principal Officers +17.20%
01:51PM  ImmunoCellular Therapeutics Awarded $19.9 Million Grant from California Institute for Regenerative Medicine (CIRM) to Fund ICT-107 Phase 3 Registration Program in Glioblastoma PR Newswire
Sep-22-15 06:00AM  ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors PR Newswire
Sep-16-15 04:10PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-14-15 06:07AM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events
Aug-26-15 01:30PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-21-15 06:00AM  ImmunoCellular Therapeutics Issues Letter to Shareholders, Highlighting Progress on Advancing ICT-107 to Phase 3 Registrational Trial PR Newswire
Aug-17-15 06:07AM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing R
Aug-14-15 12:25PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-13-15 06:00AM  ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma PR Newswire +10.57%
Aug-09-15 08:13PM  10-Q for ImmunoCellular Therapeutics Ltd. at Company Spotlight
Aug-07-15 06:35PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly Report
04:01PM  Edited Transcript of IMUC earnings conference call or presentation 6-Aug-15 9:00pm GMT
Aug-06-15 05:09PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem
05:00PM  ImmunoCellular Therapeutics Ltd Earnings Call scheduled for 5:00 pm ET today
04:01PM  ImmunoCellular Therapeutics Announces Second Quarter 2015 Financial Results PR Newswire
07:07AM  Q2 2015 ImmunoCellular Therapeutics Ltd Earnings Release - After Market Close
Jul-23-15 04:01PM  ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 PR Newswire
Jul-06-15 06:00AM  ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma PR Newswire
Jul-02-15 04:16PM  IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing other therapeutic DC vaccines, such as ICT-140 for ovarian cancer; and ICT-121 to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.